AstraZeneca Feed

2024-06-26 08:01:08 AstraZeneca: Tagrisso with the addition of chemotherapy approved in China as 1st-line treatment for patients with EGFR-mutated advanced lung cancer -0,12% | 8157 MSEK

2024-06-25 08:10:54 AstraZeneca: Tagrisso with the addition of chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer +0,84% | 13049 MSEK

2024-06-25 08:10:09 AstraZeneca: Update on ADJUVANT BR.31 Phase III trial of Imfinzi in non-small cell lung cancer +0,84% | 13049 MSEK

2024-06-25 08:00:40 AstraZeneca: Imfinzi demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial +0,84% | 13049 MSEK

2024-06-20 08:00:54 AstraZeneca: Truqap plus Faslodex approved in the EU for patients with advanced ER-positive breast cancer +0,18% | 7448 MSEK

2024-06-18 08:00:42 AstraZeneca: Update on the CAPItello-290 Phase III trial for Truqap plus chemotherapy in advanced or metastatic triple-negative breast cancer -0,75% | 7398 MSEK

2024-06-17 08:00:59 AstraZeneca: Imfinzi plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer -0,95% | 5627 MSEK

2024-06-17 07:55:14 AstraZeneca: Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial -0,95% | 5627 MSEK

2024-06-12 21:01:46 AstraZeneca: Farxiga approved in the US for the treatment of paediatric type-2 diabetes +0,12% | 8908 MSEK

2024-06-10 08:01:33 AstraZeneca: Tagrisso granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer -0,06% | 8092 MSEK

2024-06-04 22:05:48 AstraZeneca: Acquisition of Fusion completed +0,81% | 8829 MSEK

2024-06-03 08:00:32 AstraZeneca: Tagrisso with the addition of chemotherapy recommended for approval in the EU by CHMP for patients with EGFR-mutated advanced lung cancer +0,58% | 9047 MSEK

2024-06-03 07:55:06 AstraZeneca: Tagrisso reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial +0,58% | 9047 MSEK

2024-06-03 07:50:15 AstraZeneca: Imfinzi is first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo +0,58% | 9047 MSEK

2024-06-03 07:45:58 AstraZeneca: Enhertu demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy +0,58% | 9047 MSEK

2024-05-27 08:02:54 AstraZeneca: Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial -0,75% | 1121 MSEK

2024-05-22 08:02:15 AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024 -0,33% | 8633 MSEK

2024-05-21 08:02:00 AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030 +2,80% | 9408 MSEK

2024-05-20 08:00:36 AstraZeneca plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore -0,06% | 6446 MSEK

2024-05-16 08:01:17 AstraZeneca: SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population -0,27% | 8610 MSEK

2024-05-06 08:01:39 AstraZeneca completes equity investment agreement with Cellectis 0,00% | 1360 MSEK

2024-05-02 08:05:21 AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio -1,05% | 10298 MSEK

2024-05-02 08:01:26 AstraZeneca: Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial -1,05% | 10298 MSEK

2024-04-29 08:06:18 AstraZeneca: Truqap plus Faslodex recommended for approval in the EU by CHMP for patients with advanced ER-positive breast cancer +0,58% | 16073 MSEK

2024-04-29 08:01:33 AstraZeneca: Enhertu improved PFS in HER2-low and ultralow +0,58% | 16073 MSEK

2024-04-25 08:00:31 AstraZeneca: Resultat första kvartalet 2024 +6,35% | 30292 MSEK

2024-04-23 08:00:32 AstraZeneca: Voydeya approved in the EU as add-on treatment to ravulizumab or eculizumab for adults with the rare disease PNH who have residual haemolytic anaemia -0,49% | 14617 MSEK

2024-04-17 09:01:18 AstraZeneca advances the science of infectious disease protection at ECCMID 2024 +0,70% | 10232 MSEK

2024-04-16 08:02:16 AstraZeneca: Imfinzi plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial -0,67% | 8739 MSEK

2024-04-11 08:00:49 AstraZeneca increases 2024 dividend by 7% +2,62% | 12882 MSEK

2024-04-08 08:03:24 AstraZeneca: Alexion data at AAN 2024 demonstrate how Ultomiris and Soliris can transform outcomes for rare neurological diseases -0,42% | 7253 MSEK

2024-04-08 08:00:55 AstraZeneca: Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours -0,42% | 7253 MSEK

2024-04-05 08:01:08 AstraZeneca: Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial -0,80% | 9095 MSEK

2024-04-02 08:06:34 AstraZeneca: Voydeya approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular haemolysis in adults with the rare disease PNH -0,90% | 9427 MSEK

2024-04-02 08:01:44 AstraZeneca: Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer -0,90% | 9427 MSEK

2024-03-27 08:07:58 AstraZeneca: Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer +3,24% | 12824 MSEK

2024-03-27 08:02:13 AstraZeneca: Beyfortus approved in Japan for the prevention of RSV disease in infants +3,24% | 12824 MSEK

2024-03-25 08:03:35 AstraZeneca: Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) -0,39% | 8041 MSEK

2024-03-21 15:11:47 AstraZeneca: Tagrisso with the addition of chemotherapy showed favourable trend in overall survival in EGFR-mutated advanced lung cancer with further follow up in FLAURA2 Phase III trial +1,86% | 8576 MSEK

2024-03-19 08:02:12 AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer -0,76% | 9411 MSEK

2024-03-18 13:08:48 AstraZeneca: Lynparza and Imfinzi demonstrated strong clinical benefit and more than doubled median duration of response vs. chemotherapy in patients with pMMR advanced or recurrent endometrial cancer +0,73% | 10261 MSEK

2024-03-14 08:02:19 AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline +0,18% | 10245 MSEK

2024-03-07 12:00:00 AstraZeneca: Notice of AGM +0,78% | 9848 MSEK

2024-03-04 08:02:38 AstraZeneca: Two datopotamab deruxtecan applications validated in the EU for patients with advanced nonsquamous non-small cell lung cancer or HR-positive, HER2-negative breast cancer +0,26% | 7093 MSEK

2024-02-26 08:01:39 AstraZeneca: Voydeya recommended for approval in the EU by CHMP as add-on treatment to ravulizumab or eculizumab for adults with PNH who have residual haemolytic anaemia +0,04% | 14828 MSEK

2024-02-22 14:16:30 AstraZeneca: Acquisition of Gracell completed -0,97% | 24388 MSEK

2024-02-21 08:00:00 AstraZeneca: Filing of Form 20-F with SEC -0,96% | 8196 MSEK

2024-02-19 16:01:28 AstraZeneca: Acquisition of Icosavax Completed +2,80% | 11019 MSEK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

AstraZeneca

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden